Sutro Biopharma, Inc. STRO
Analyst Ratings
- Consensus
- Buy — 9 Buy · 0 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $47.33 (+430.6% upside)
Key Stats
- Today's Range
- $8.65 – $9.57
- 50-Day Range
- $8.11 – $19.46
- 52-Week Range
- $7.15 – $43.85
- Volume
- 210K shs
- Average Volume
- 337K shs
- Market Cap
- $154.73 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.07%
- Days to Cover
- 1.00
About Sutro Biopharma, Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Related Stocks
Compare head-to-head: STRO vs AMGN·STRO vs MRNA·STRO vs HALO·STRO vs KYMR
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
